Sign Out
Pregnancy: Insufficient data exist on the use of nebivolol in human pregnancy to determine its potential harmfulness. Animal studies have not shown any indication of harmful effects, other than on the basis of its pharmacological properties, Beta-blockers reduce placental perfusion, which may result in intrauterine fetal death and in immature and premature delivery. In addition, adverse effects (hypoglycemia and bradycardia) may occur in the fetus and the neonate. There is an increased risk of cardiac and pulmonary complications in the neonate in the postnatal period. Therefore, nebivolol should not be used during pregnancy.
Lactation: Most Beta-blockers, particularly lipophilic compounds like nebivolol and its active metabolites, pass into breast milk although to a variable extent. Since it is not known whether nebivolol is excreted into human milk, the use of nebivolol when breast feeding is contra-indicated. Animal studies have shown that nebivolol is excreted in breast milk.
